{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"description":"HAI in blood at week 21 for all variants","groups":[{"description":"Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"OG000","title":"Arm I (Trivalent Influenza Vaccine, Prevnar)"},{"description":"Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"OG001","title":"Arm II (Trivalent Influenza Vaccine, Prevnar)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"21 weeks","title":"Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)","type":"PRIMARY","unitOfMeasure":"Participants"}